Conditions: HIV-associated Myelopathy
Keywords: HIV associated myelopathy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 12
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.

Detailed description:
The purpose of this study is to determine whether or not intravenous immunoglobulin (lVlg), brand name Privigen, is effective in treating a disorder called HIV-associated myelopathy (HIVM). This drug is currently not approved by the Food and Drug Administration (FDA) for treating this disorder.

HIVM is a spinal cord disease that occurs at any stage of HIV infection. It is not known what causes this condition, but symptoms can include weakness in the lower body and problems with frequent urination or problems with bowel function, trouble walking or performing sexually.

Arms:
arm 1: Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen® arm 2: Saline 2gr/kg over 2 days of saline

Interventions: intervention 1: Intravenous Immunoglobulin intervention 2: Placebo
Intervention descriptions: intervention 1: Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen® intervention 2: Placebo - 2gr/kg over 2 days of saline

Protocol document: